What does PHARMACLIC ASSETS do?

PHARMACLIC ASSETS is a pharmacy in Evere. Public Limited, started on 13 December 2005, 1 establishment.

What is the address of PHARMACLIC ASSETS?

The registered office of PHARMACLIC ASSETS is located at Cicerolaan 7, 1140 Evere.

Is PHARMACLIC ASSETS still active?

Yes. According to the CBE (16 September 2026) PHARMACLIC ASSETS is active, legal situation “Normale toestand”, started on 13 December 2005.

Is PHARMACLIC ASSETS registered on Peppol?

Yes, PHARMACLIC ASSETS is registered on the Peppol network with ID 0208:0877869301.

What is the enterprise number of PHARMACLIC ASSETS?

The enterprise number of PHARMACLIC ASSETS is BE0877869301.

When was PHARMACLIC ASSETS founded?

PHARMACLIC ASSETS was founded on 13 December 2005.

Who are the directors of PHARMACLIC ASSETS?

According to the 2025 annual accounts, the directors of PHARMACLIC ASSETS are: Medi-Market Group SA.

Is PHARMACLIC ASSETS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 December 2005; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMACLIC ASSETS make in 2025?

PHARMACLIC ASSETS posted a profit after taxes of € 114,983 in financial year 2025.

What is the revenue of PHARMACLIC ASSETS?

As a small company, PHARMACLIC ASSETS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 888,398.

How many employees does PHARMACLIC ASSETS have?

According to the 2025 annual accounts, PHARMACLIC ASSETS has 0 full-time equivalents (FTE).

PHARMACLIC ASSETS (Public Limited) - Evere - BE0877869301

Dossier PHARMACLIC ASSETS, printed on 16 September 2026 from databakkes.be/en/0877869301/pharmaclic-assets. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Busy address KBO

14 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

PHARMACLIC ASSETS from Evere, company number BE0877869301, closed financial year 2025 with a result of € 114,983 after tax. For that financial year PHARMACLIC ASSETS recorded a gross margin of € 888,398 and equity of € -877,138. Compared with financial year 2024, the result moved from € -90,908 to € 114,983. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Caution

€ -877,138

▲ € 114,983 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 114,983

▲ still € 90,908 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 0

▼ 100% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -1 million.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2.1 million

▼ 20% vs 2024

€ 478,004 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 565,100

▲ 279% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 767,242 Revenue 2022: € 767,242 First fiscal year in the series	€ 1,121,176 Revenue 2023: € 1,121,176 ▲ 46% vs 2022 (€ 767,242) Favourable step	-	-
Gross margin	-	-	€ 996,862 Gross margin 2024: € 996,862 First fiscal year in the series	€ 888,398 Gross margin 2025: € 888,398 ▼ 11% vs 2024 (€ 996,862) Unfavourable step	▼ 11%
Profit after taxes	€ 136,071 Profit after taxes 2022: € 136,071 First fiscal year in the series	€ -137,966 Profit after taxes 2023: € -137,966 ▼ € 274,037 vs 2022 (€ 136,071) Unfavourable step	€ -90,908 Profit after taxes 2024: € -90,908 ▲ € 47,059 vs 2023 (€ -137,966) Favourable step	€ 114,983 Profit after taxes 2025: € 114,983 ▲ € 205,890 vs 2024 (€ -90,908) Favourable step	▲ € 205,890
Equity	€ -763,248 Equity 2022: € -763,248 First fiscal year in the series	€ -901,214 Equity 2023: € -901,214 ▼ € 137,966 vs 2022 (€ -763,248) Unfavourable step	€ -992,121 Equity 2024: € -992,121 ▼ € 90,908 vs 2023 (€ -901,214) Unfavourable step	€ -877,138 Equity 2025: € -877,138 ▲ € 114,983 vs 2024 (€ -992,121) Favourable step	▲ € 114,983
Total debts	€ 15,349,390 Total debts 2022: € 15,349,390 First fiscal year in the series	€ 15,149,978 Total debts 2023: € 15,149,978 ▼ 1% vs 2022 (€ 15,349,390) Favourable step	€ 14,570,745 Total debts 2024: € 14,570,745 ▼ 4% vs 2023 (€ 15,149,978) Favourable step	€ 14,863,216 Total debts 2025: € 14,863,216 ▲ 2% vs 2024 (€ 14,570,745) Unfavourable step	▲ 2%
Cash	€ 3,119 Cash 2022: € 3,119 First fiscal year in the series	€ 8,314 Cash 2023: € 8,314 ▲ 167% vs 2022 (€ 3,119) Favourable step	€ 2,700 Cash 2024: € 2,700 ▼ 68% vs 2023 (€ 8,314) Unfavourable step	€ 0 Cash 2025: € 0 ▼ 100% vs 2024 (€ 2,700) Unfavourable step	▼ 100%
Retained profit	€ -888,248 Retained profit 2022: € -888,248 First fiscal year in the series	€ -1,026,214 Retained profit 2023: € -1,026,214 ▼ € 137,966 vs 2022 (€ -888,248) Unfavourable step	€ -1,117,121 Retained profit 2024: € -1,117,121 ▼ € 90,908 vs 2023 (€ -1,026,214) Unfavourable step	€ -1,002,138 Retained profit 2025: € -1,002,138 ▲ € 114,983 vs 2024 (€ -1,117,121) Favourable step	▲ € 114,983
Bank debt	€ 3,527,574 Bank debt 2022: € 3,527,574 First fiscal year in the series	€ 3,045,812 Bank debt 2023: € 3,045,812 ▼ 14% vs 2022 (€ 3,527,574) Favourable step	€ 2,553,179 Bank debt 2024: € 2,553,179 ▼ 16% vs 2023 (€ 3,045,812) Favourable step	€ 2,055,176 Bank debt 2025: € 2,055,176 ▼ 20% vs 2024 (€ 2,553,179) Favourable step	▼ 20%
Balance sheet total	€ 14,586,142 Balance sheet total 2022: € 14,586,142 First fiscal year in the series	€ 14,248,764 Balance sheet total 2023: € 14,248,764 ▼ 2% vs 2022 (€ 14,586,142) Unchanged	€ 13,578,624 Balance sheet total 2024: € 13,578,624 ▼ 5% vs 2023 (€ 14,248,764) Unchanged	€ 13,986,078 Balance sheet total 2025: € 13,986,078 ▲ 3% vs 2024 (€ 13,578,624) Unchanged	▲ 3%

Key figures of PHARMACLIC ASSETS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACLIC ASSETS?

What happened at PHARMACLIC ASSETS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 114,983. Source: NBB ↗
2021 Medi-Market Group SA became a director. NBB
Dec 13, 2005 New establishment in Charleroi. KBO
Dec 13, 2005 Start of the company according to the CBE. KBO

In short

From € 136,071 profit in 2022 to € 114,983 profit in 2025.

Best year ever: 2022, with € 136,071 profit.

Original PDFs at the National Bank ↗

A new publication or filing at PHARMACLIC ASSETS? We notify you, reason included.

Follow PHARMACLIC ASSETS

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Medi-Market Group 100%

PHARMACLIC ASSETS

Pharmacie by Medi-Market Group - Evere SA 100%

Parapharmacity SRL 100%

Medi-Market Mons Grand Pré 100%

Pharmacie by Medi-Market Group - Korbeek-Lo 100%

Behind PHARMACLIC ASSETS is Medi-Market Group SA. The shares are held by Medi-Market Group (100%). It owns 100% of Pharmacie by Medi-Market Group - Evere SA, 100% of Parapharmacity SRL, 100% of Medi-Market Mons Grand Pré, 100% of Pharmacie by Medi-Market Group - Korbeek-Lo, 100% of Pharmacie by Medi-Market Group - Gosselies SA and 100% of Pharmacie by Medi-Market Group - Zemst SA itself.

See the full network in the app